Bactiguard targets at least SEK 600 million in revenue and SEK 200 million EBITDA by 2030, focusing on license partnerships in high-need therapeutic areas and leveraging operational scale for growth. Partnerships with major MedTech firms and a strong wound management portfolio support these goals.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.